A clinical trial to assess the safety and efficacy of an oral medication called Etrasimod for moderately active ulcerative colitis (UC).
About this study
The purpose of this study was to assess the efficacy and safety of Etrasimod in participants with moderately active ulcerative colitis (UC).
Etrasimod is designed to block the movement of some kind of cells in your body (part of your immune system called lymphocytes) to areas of inflammation in the colon.
Etrasimod is an experimental treatment. This means that it is not approved treatment for UC by Regulatory Authorities such as the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States.
Enrolment closed
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.